Sign In
Buy IMMX
$8.32
-0.230 (-2.69%)
At Close: Jul 31, 2026
Immix Biopharma on Track to Dose NXC-201 Patients in United States
09:32am, Thursday, 18'th Apr 2024
Scheduling U.S. site initiation visits April and May 2024 On track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 at New York City lead site and other leading U.S. sites mid-20
LOS ANGELES, April 15, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company tra
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
09:46am, Wednesday, 20'th Mar 2024
LOS ANGELES, CA, March 20, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
09:35am, Tuesday, 05'th Mar 2024
Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United States today in their own words Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United St
Immix Biopharma 12 Month Review Progress Update
09:31am, Wednesday, 21'st Feb 2024
LOS ANGELES, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
04:45pm, Thursday, 08'th Feb 2024
LOS ANGELES, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering pers
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
09:37am, Wednesday, 07'th Feb 2024
European Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EU Access to the EU centralized authorization procedure Reduced fees for EU pr
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
10:30pm, Monday, 05'th Feb 2024
LOS ANGELES, CA, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering pers
Immix Biopharma Announces Proposed Public Offering of Common Stock
03:20pm, Monday, 05'th Feb 2024
LOS ANGELES, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (the “Company”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, t
Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products
08:35am, Wednesday, 24'th Jan 2024
LOS ANGELES, CA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), a clinical-stage biopharmaceutical company trailblaz
Dr. Radic led and authored landmark study demonstrating applicability of CAR-Ts in autoimmune diseases published in Science Translational Medicine, 2019 Dr. Radic is a recognized thought leader in aut
100% (10/10) overall response rate (ORR) and 70% (7/10) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 6 lines of prior
Immix Biopharma: Seeking Catalysts To Propel Out Of Microcap Status
02:02am, Sunday, 03'rd Dec 2023
Immix Biopharma is a biotech company focused on developing CAR-T and other cell-based therapies for cancers and heme disorders. Their most advanced project is NXC-201, a BCMA-targeted CAR-T natural ki
Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit
09:46am, Thursday, 30'th Nov 2023
LOS ANGELES, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) a clinical-stage biopharmaceutical company pioneering personal
Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing
03:48pm, Tuesday, 28'th Nov 2023 InvestorsHub
Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing NEXICART-2 to expand studies of NXC-201 in relapsed/refractory AL Amyloidosis to U.S. sites based on IND clearance72 patients previously dosed with NXC-201 ex-U.S.First CAR-T program for light-chain (AL) AmyloidosisFavorable tolerability enables expansion into autoimmune indicationsLOS ANGELES, Nov. 28, 2023 -- InvestorsHub NewsWire -- Immix Biopharma, Inc. (Nasdaq:IMMX) ("ImmixBio", "Compan...
